Ticker
ABIO

Price
2.34
Stock movement down
-0.08 (-3.30%)
Company name
ARCA Biopharma Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
33.72M
Ent value
-12.26M
Price/Sales
-
Price/Book
0.70
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-24.52%
3 year return
-25.19%
5 year return
-34.76%
10 year return
-37.49%
Last updated: 2022-08-25

DIVIDENDS

ABIO does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book0.70
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count14.41M
EPS (TTM)-1.28
FCF per share (TTM)-1.24

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-18.51M
Net income (TTM)-18.49M
EPS (TTM)-1.28
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash49.06M
Net receivables0.00
Total current assets50.54M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets51.01M
Accounts payable1.01M
Short/Current long term debt357.00K
Total current liabilities2.72M
Total liabilities3.08M
Shareholder's equity47.94M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-17.84M
Capital expenditures (TTM)39.00K
Free cash flow (TTM)-17.87M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-38.58%
Return on Assets-36.25%
Return on Invested Capital-38.58%
Cash Return on Invested Capital-37.29%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.38
Daily high2.42
Daily low2.31
Daily Volume48K
All-time high5726700.00
1y analyst estimate7.00
Beta2.03
EPS (TTM)-1.28
Dividend per share-
Ex-div date1 May 2006
Next earnings date31 Oct 2022

Downside potential

Loading...
Downside potential data
ABIOS&P500
Current price drop from All-time high-100.00%-12.18%
Highest price drop-100.00%-56.47%
Date of highest drop25 Aug 20229 Mar 2009
Avg drop from high-93.75%-11.38%
Avg time to new high274 days12 days
Max time to new high5666 days1805 days
COMPANY DETAILS
ABIO (ARCA Biopharma Inc) company logo
Marketcap
33.72M
Marketcap category
Small-cap
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Employees
17
Investor relations
-
SEC filings
CEO
Michael R. Bristow
Country
USA
City
Westminster
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIR...
August 2, 2022
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
July 18, 2022
WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-We...
June 21, 2022
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 20...
May 5, 2022
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE...
May 2, 2022
WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therap...
April 18, 2022
Press release Paris La Défense, 5 April 2022 Governance changes Marie-Claire Daveu has informed Albioma today of her intention to resign from the Board of Directors with effect from 31 July 2022, with...
April 5, 2022
ARCA biopharma Inc (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized w...
April 1, 2022
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reductio...
March 31, 2022
Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March 2022WESTMINSTER, Colo., March 14, 2022 (GLOBE NEW...
March 14, 2022
Next page